An international team of researchers has identified a potential new target for osteoporosis treatment, offering hope for the millions worldwide affected by the debilitating bone disease.Published in Signal Transduction and Targeted Therapy,the study details how activating a specific receptor,GPR133,boosted bone strength in laboratory models-a finding that could lead to therapies promoting natural bone rebuilding with fewer side effects than current options. The research, a collaboration between scientists in Germany and China, investigated the receptor’s role in regulating bone density and points toward a novel pathway for combating age-related bone loss and possibly strengthening bones weakened by conditions like menopause.
- Eliminar los cálculos renales sin dolor ni efectos secundarios podría estar más cerca que nunca gracias a este gel magnético
- Sigue a El Confidencial en Google Discover para enterarte de todas las noticias
A new approach to strengthening bone and combating osteoporosis is showing promise, according to an international team of scientists. Researchers have demonstrated in mice that activating a specific cellular receptor can bolster bone tissue. The findings, published in Signal Transduction and Targeted Therapy, offer a potential new avenue for treating the debilitating condition that affects millions worldwide.
The study, a collaboration between the University of Leipzig and the University of Shandong, investigated how the receptor regulates the delicate balance between bone-building cells and those responsible for bone breakdown. Researchers found that the absence of the gene encoding GPR133 led to early bone density loss, mirroring the patterns seen in patients diagnosed with osteoporosis. This suggests the receptor plays a critical role in maintaining skeletal health.
Targeting an Under-Explored Pathway
In laboratory tests, the application of a compound called AP503 specifically activated the GPR133 receptor, boosting the activity of osteoblasts (bone-forming cells) and reducing the action of osteoclasts (bone-resorbing cells). This response led to increased bone strength in both healthy animals and models exhibiting bone deterioration comparable to that seen in human osteoporosis.
Samples of blood used to test the compound (University of Nottingham)
“Using the substance AP503, which was recently identified through computational analysis as a GPR133 stimulator, we were able to significantly increase bone strength in both healthy and osteoporotic mice,” said Professor Ines Liebscher, who led the research. She added that this pathway could also be used to strengthen bones weakened after menopause, a period often associated with accelerated bone loss.
A Compound with Regenerative Potential
The researchers explain that activating GPR133 acts as a natural bone-strengthening mechanism that can also respond to the mechanical stimulus of exercise, further enhancing tissue regeneration. According to researcher Juliane Lehmann, “The recently demonstrated parallel strengthening of bone once again highlights the great potential of this receptor for medical applications in a growing population.”
TE PUEDE INTERESAR
El tratamiento para corregir la miopía sin láser ni cirugía está más cerca que nunca
R. Badillo
Current osteoporosis treatments primarily focus on slowing disease progression and often come with significant side effects. The AP503 compound, however, offers a potential alternative by promoting natural bone rebuilding without disrupting the body’s normal physiological balance. This makes it a promising target for future therapies aimed at older adults.
